Autolus Therapeutics FY2026 AUCATZYL net product revenue expected to be more than $150.000M
Benzinga Newsdesk 2 hours ago
NewsGuidance
Autolus Therapeutics (NASDAQ:AUTL) FY2026 AUCATZYL net product revenue expected to be more than $150.000M.
Autolus Therapeutics (NASDAQ:AUTL) FY2026 AUCATZYL net product revenue expected to be more than $150.000M.